<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-2176</journal-id>
<journal-title><![CDATA[Revista Cubana de Oftalmología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Oftalmol]]></abbrev-journal-title>
<issn>0864-2176</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-21762022000200016</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Rituximab: alternativa eficaz para la querotopatía ulcerativa periférica]]></article-title>
<article-title xml:lang="en"><![CDATA[Rituximab: effective alternative for peripheral ulcerative kerotopathy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Monroy]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garcia-Navarro]]></surname>
<given-names><![CDATA[Damian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Munuera Rufás]]></surname>
<given-names><![CDATA[Inés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario &#8220;Miguel Servet&#8221;  ]]></institution>
<addr-line><![CDATA[ Zaragoza]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Zaragoza  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>35</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-21762022000200016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-21762022000200016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-21762022000200016&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El desarrollo de los fármacos biológicos ha permitido controlar de manera óptima las manifestaciones oftalmológicas de las enfermedades autoinmunes, el conocimiento de nuevas vías patogénicas y de nuevas dianas terapéuticas lo que está suponiendo una revolución en el tratamiento médico de numerosas entidades y donde la oftalmología no es una excepción. Se presenta el caso clínico de una paciente con artritis reumatoide con mal control y afectación multisistémica que presentó una queratopatía ulcerativa periférica de mal control que respondió con tratamiento biológico diferente al tradicionalmente usado: el rituximab.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The development of biological drugs has allowed optimal control of the ophthalmologic manifestations of autoimmune diseases, the knowledge of new pathogenic pathways and new therapeutic targets, which is leading to a revolution in the medical treatment in numerous entities and where ophthalmology is no exception. We present the clinical case of a patient with poorly controlled rheumatoid arthritis and multisystemic condition. The patient presented a poorly controlled peripheral ulcerative keratopathy that responded to a different biological treatment than the one traditionally used: rituximab.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[queratopatía ulcerativa periférica]]></kwd>
<kwd lng="es"><![CDATA[córnea]]></kwd>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[rituximab]]></kwd>
<kwd lng="es"><![CDATA[antiCD20]]></kwd>
<kwd lng="en"><![CDATA[peripheral ulcerative keratopathy]]></kwd>
<kwd lng="en"><![CDATA[Cornea]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Rituximab]]></kwd>
<kwd lng="en"><![CDATA[antiCD20]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kasper]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jameson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Harrison Principios de medicina interna, México DF, McGrawHill]]></source>
<year>2018</year>
<edition>18</edition>
<page-range>2738-51</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Artifoni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rothschild]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Brézin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guillevin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Puéchal]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ocular inflammatory diseases associated with rheumatoid arthritis]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2014</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>108-16</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knox Cartwright]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Tole]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Georgoudis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peripheral ulcerative keratitis and corneal melt a 10-year single center review with historical comparison]]></article-title>
<source><![CDATA[Cornea]]></source>
<year>2014</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-31</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ishii]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Takada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yokokura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shirota]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fujii]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Harigae]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era a series of eight cases and literature review]]></article-title>
<source><![CDATA[Int J Rheum Dis]]></source>
<year>2017</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>225-30</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thorne]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Scleritis and peripheral ulcerative keratitis]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2007</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>835-54</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stylianides]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Goodson]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis-associated corneal ulceration mortality and graft survival]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2013</year>
<volume>120</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>682-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thorne]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Scleritis and peripheral ulcerative keratitis]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2007</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>835-54</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Salvador]]></surname>
<given-names><![CDATA[VB]]></given-names>
</name>
<name>
<surname><![CDATA[Bagchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tushabe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Abrudescu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid arthritis-associated corneal ulceration with superimposed infection by methicillin-resistant Staphylococcus aureus a complicated type of corneal melt]]></article-title>
<source><![CDATA[Am J Case Rep]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>523-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Pflugfelder]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab]]></article-title>
<source><![CDATA[Cornea]]></source>
<year>2005</year>
<volume>24</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>742-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Beltrán]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Costa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab en queratitis ulcerativa periférica asociada a artritis reumatoide]]></article-title>
<source><![CDATA[Arch Soc Esp Oftalmol]]></source>
<year>2011</year>
<volume>86</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>118-20</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kraus]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Culican]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of biologic agents in ocular manifestations of rheumatic disease]]></article-title>
<source><![CDATA[Int J Rheumatol]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>Grupo GUIPCAR de trabajo de la GPC para el Manejo de Pacientes con Artritis Reumatoide</collab>
<article-title xml:lang=""><![CDATA[Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide]]></article-title>
<source><![CDATA[Sociedad Española de Reumatología]]></source>
<year>2018</year>
<page-range>87-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porter]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[van Melckebeke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dale]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Messow]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[McConnachie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT) an open-label, randomised controlled, non-inferiority, trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10041</numero>
<issue>10041</issue>
<page-range>239-47</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
